Ascentage Pharma Statements
68
Ascentage Pharma Income Statement
B
M
CNY (except Earnings per share)
Financial
Revenue
Cost of sales
Gross profit
Research and development
Selling, general and administrative
Total operating expenses
Operating income
Interest expense
Other income
Income before tax
Provision for income taxes
Net income
Diluted earnings per share
Shares outstanding after dilution
79.283
100
12.389
15.6
66.894
84.4
397.16
500.9
201.8
254.5
585.7
738.7
-518.8
-654.4
-14.459
-18.2
—
0
-533.26
-672.6
-9.896
-12.5
-523.29
-660.02
-1.804
290.05
142.7
100
18.154
12.7
124.55
87.3
309.81
217.1
174.66
122.4
480.48
336.7
-355.93
-249.4
-43.67
-30.6
—
0
-399.6
-280.03
2.746
1.9
-402.35
-282
-1.465
274.55
113.95
100
16.977
14.9
96.971
85.1
401.69
352.5
174.33
153
555.4
487.4
-458.43
-402.3
-26.482
-23.2
—
0
-484.92
-425.6
-8.73
-7.7
-476.19
-417.9
-1.806
263.66
95.763
100
5.021
5.2
90.742
94.8
341.41
356.5
153.69
160.5
497.65
519.7
-406.9
-424.9
2.58
2.7
—
0
-402.25
-420.05
4.482
4.7
-406.73
-424.7
-1.543
263.67
14.945
100
0.739
4.9
14.206
95.1
448.95
3004
116.74
781.1
561.41
3756.5
-547.2
-3661.4
89.327
597.7
—
0
-457.87
-3063.7
-52.131
-348.8
-405.74
-2714.9
-1.548
262.17
12.965
100
2.589
20
10.376
80
317.54
2449.2
74.52
574.8
383.28
2956.3
-372.91
-2876.2
-1.471
-11.3
—
0
-374.38
-2887.6
2.306
17.8
-376.68
-2905.4
-1.525
247.06
9.837
100
1.966
20
7.871
80
313.12
3183
68.643
697.8
372.31
3784.8
-364.44
-3704.8
8.97
91.2
—
0
-355.47
-3613.6
2.959
30.1
-358.43
-3643.7
-1.608
222.92
2.613
100
—
0
—
0
251.46
9623.2
61.699
2361.2
332.03
12707
-329.42
-12607
9.442
361.3
—
0
-319.98
-12245.6
-0.801
-30.7
-319.18
-12215
-1.528
208.9
12.196
100
2.096
17.2
10.1
82.8
264.9
2172
99.853
818.7
863.88
7083.3
-853.78
-7000.5
5.577
45.7
—
0
-848.2
-6954.7
-0.801
-6.6
-847.4
-6948.2
-21.976
38.561
2.317
100
—
0
2.317
100
198.98
8587.9
61.79
2666.8
645.13
27843.2
-642.81
-27743.2
8.693
375.2
—
0
-634.12
-27368
-0.801
-34.6
-633.32
-27333.4
-3.25
194.89